LHDX · Lucira Health, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 |
|---|---|
| Revenue | $93.30M |
| Cost of Revenue | $1.94M |
| Gross Profit | ($1.67M) |
| R&D | $24.62M |
| SG&A | $5.63M |
| Total Operating Expenses | $30.25M |
| D&A | $280.0K |
| Operating Income | ($31.93M) |
| Interest Expense | $46.0K |
| Income Tax | $17.0K |
| Net Income | ($37.35M) |
| EPS - Basic | - |
| EPS - Diluted | - |
Balance Sheet
| Line item | FY 2021 |
|---|---|
| Cash & Equivalents | $105.98M |
| Accounts Receivable | $27.25M |
| Inventory | $50.78M |
| Accounts Payable | $19.37M |
| Current Assets | $206.28M |
| Total Assets | $240.35M |
| Current Liabilities | $50.33M |
| Long-term Debt | - |
| Total Liabilities | $51.55M |
| Stockholders' Equity | $188.80M |
| Retained Earnings | ($128.54M) |
Cash Flow
| Line item | FY 2021 |
|---|---|
| Operating Cash Flow | ($32.52M) |
| Investing Cash Flow | ($18.81M) |
| Financing Cash Flow | $107.79M |
| CapEx | $18.81M |
| Free Cash Flow | ($51.34M) |
Ratios
| Metric | FY 2021 |
|---|---|
| Profitability | |
| Gross margin | -1.8% |
| Operating margin | -34.2% |
| EBITDA margin | -33.9% |
| Net margin | -40.0% |
| Free cash flow margin | -55.0% |
| FCF / Net income | 1.37 |
| R&D / Revenue | 26.4% |
| SG&A / Revenue | 6.0% |
| Effective tax rate | - |
| Return on assets | -15.5% |
| Return on equity | -19.8% |
| Return on invested capital | - |
| Liquidity | |
| Current ratio | 4.10 |
| Quick ratio | 3.09 |
| Cash ratio | 2.11 |
| Leverage | |
| Debt / Equity | - |
| Debt / Assets | - |
| Debt / EBITDA | - |
| Interest coverage | -694.0x |
| Equity multiplier | 1.27 |
| Liabilities / Assets | 0.21 |
| Efficiency | |
| Asset turnover | 0.39 |
| Inventory turnover | 0.04 |
| Days sales outstanding | 107d |
| Days inventory outstanding | 9548d |
| Days payable outstanding | 3643d |
| Cash conversion cycle | 6012d |
| Valuation | |
| P / E | - |
| P / B | - |
| P / S | - |
| EV / EBITDA | - |
| Growth | |
| Revenue growth (YoY) | - |
| Revenue CAGR (3y) | - |
| Revenue CAGR (5y) | - |
| Gross profit growth (YoY) | - |
| Operating income growth (YoY) | - |
| Net income growth (YoY) | - |
| EPS growth (YoY) | - |
| EPS CAGR (3y) | - |
| EPS CAGR (5y) | - |
| FCF growth (YoY) | - |
| FCF CAGR (5y) | - |
| Book value growth (YoY) | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Geographic
$93.06M totalUS$74.79M · 80.4%
CA$13.07M · 14.0%
All Other Countries$5.20M · 5.6%
Stability scores
Altman Z′
FY 2021 · bankruptcy risk
1.53
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2021 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- -ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- -Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: In Vitro & In Vivo Diagnostic Substances
Comparing Lucira Health against the 5 most active filers in the same SIC group.